Last reviewed 2026-05-27 · How we verify

vitamin c 20%

vitamin c 20% is a Vitamin / Antioxidant / Micronutrient Small molecule drug developed by Kasr El Aini Hospital. It is currently FDA-approved for Vitamin C deficiency / Scurvy, Adjunctive antioxidant support in critical illness or post-operative recovery, Immune support and general nutritional supplementation. Also known as: vitamin c 20% global cosmetic solutions.

Vitamin C (ascorbic acid) acts as a reducing agent and antioxidant, donating electrons to neutralize free radicals and support collagen synthesis and immune function.

Vitamin C is a supplement that has been studied in various clinical trials, including those examining its effects on conditions such as infertility and tendinitis of the shoulder. According to ClinicalTrials.gov, vitamin C has been tested as an intervention in studies, but its specific effects and mechanisms are not clearly defined in the provided information.

At a glance

Mechanism of action

Vitamin C is an essential micronutrient that functions as a cofactor for enzymatic reactions, particularly in collagen cross-linking and hydroxylation. As a potent antioxidant, it scavenges reactive oxygen species and regenerates other antioxidants like vitamin E. The 20% formulation is typically administered intravenously for high-dose supplementation in clinical settings.

Approved indications

• Vitamin C deficiency / Scurvy
• Adjunctive antioxidant support in critical illness or post-operative recovery
• Immune support and general nutritional supplementation

Common side effects

• Hyperoxaluria
• Kidney stone formation (with chronic high-dose use)
• Diarrhea
• Nausea
• Hemolysis (in G6PD deficiency)

Key clinical trials

• A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
• Influence of Obesity on Endogenous Oxalate Synthesis (NA)
• Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
• Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients (PHASE2)
• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
• High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) (PHASE1)
• Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
• Assessing the Impact of Herbal Supplement on Fatigue and Disease Activity in SLE: Results From an 8-Week Randomized Trial (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• vitamin c 20% CI brief — competitive landscape report
• vitamin c 20% updates RSS · CI watch RSS
• Kasr El Aini Hospital portfolio CI

Frequently asked questions about vitamin c 20%

Related

• Drug class: All Vitamin / Antioxidant / Micronutrient drugs
• Manufacturer: Kasr El Aini Hospital — full pipeline
• Therapeutic area: All drugs in Nutritional supplementation / General health
• Indication: Drugs for Vitamin C deficiency / Scurvy
• Indication: Drugs for Adjunctive antioxidant support in critical illness or post-operative recovery
• Indication: Drugs for Immune support and general nutritional supplementation
• Also known as: vitamin c 20% global cosmetic solutions

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing